» Articles » PMID: 12594223

The Oncogenic Fusion Protein-tyrosine Kinase ZNF198/fibroblast Growth Factor Receptor-1 Has Signaling Function Comparable with Interleukin-6 Cytokine Receptors

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Feb 21
PMID 12594223
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The reciprocal t(8;13) chromosome translocation results in a fusion gene (FUS) in which the N-terminal half of the zinc finger protein ZNF198 is combined with the cytoplasmic domain of the fibroblast growth factor receptor-1 (FGFR1). Expression of FUS is suggested to provide growth-promoting activity to myeloid cells similar to the activity of hematopoietic cytokine receptors. This study determined the specificity of FUS to activate signal transduction pathways. Because no tumor cell line expressing FUS was available, the mode of FUS action was identified in cells transiently and stably transfected with an expression vector for FUS. FUS acted as a constitutively active protein-tyrosine kinase and mediated phosphorylation of STAT1, 3, and 5 but not STAT4 and 6. The same specificity but lower activity was determined for normal FGFR1. STAT activation by FUS, similar to that by interleukin-6-type cytokines, promoted STAT-specific induction of genes. The functionality of FUS, as well as the relative recruitment of STAT isoforms, was determined by the dimerizing function of the zinc finger domain. Replacement of the ZNF198 portion by the Bcr portion as present in the t(8;22) translocation shifted the signaling toward a more prominent STAT5 activation. This study documents that both gene partners forming the fusion oncogene define the activity and the signaling specificity of the protein-tyrosine kinase of FGFR1.

Citing Articles

Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis.

Hu T, Cheng B, Matsunaga A, Zhang T, Lu X, Fang H Exp Hematol Oncol. 2024; 13(1):49.

PMID: 38730491 PMC: 11084112. DOI: 10.1186/s40164-024-00514-6.


Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers.

Brown L, Ekert P, Fleuren E Oncogene. 2023; 42(23):1875-1888.

PMID: 37130917 PMC: 10244177. DOI: 10.1038/s41388-023-02705-7.


The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy.

Li T, Zhang G, Zhang X, Lin H, Liu Q Front Oncol. 2022; 12:1015792.

PMID: 36408177 PMC: 9669583. DOI: 10.3389/fonc.2022.1015792.


A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.

Cai B, Liu Y, Chong Y, Mori S, Matsunaga A, Zhang H Mol Cancer. 2022; 21(1):156.

PMID: 35906694 PMC: 9336057. DOI: 10.1186/s12943-022-01628-3.


A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.

Yamanaka S, Horiuchi Y, Matsuoka S, Kido K, Nishino K, Maeno M Nat Commun. 2022; 13(1):183.

PMID: 35013300 PMC: 8748630. DOI: 10.1038/s41467-021-27818-z.